Primary and Metastatic Brain Tumours Assessed with the Brain and Torso [18F]FDG PET/CT Study Protocol-10 Years of Single-Institutional Experiences

Agata Pietrzak; Andrzej Marszałek; Tomasz Piotrowski; Adrianna Medak; Katarzyna Pietrasz; Julia Wojtowicz; Hubert Szweda; Krzysztof Matuszewski; Witold Cholewiński

doi:10.3390/ph14080722

Primary and Metastatic Brain Tumours Assessed with the Brain and Torso [¹⁸F]FDG PET/CT Study Protocol-10 Years of Single-Institutional Experiences

Pharmaceuticals (Basel). 2021 Jul 26;14(8):722. doi: 10.3390/ph14080722.

Authors

Affiliations

¹ Electroradiology Department, Poznan University of Medical Sciences, 61-866 Poznan, Poland.
² Nuclear Medicine Department, Greater Poland Cancer Centre, 61-866 Poznan, Poland.
³ Oncologic Pathology and Prophylaxis Department, Poznan University of Medical Sciences and Greater Poland Cancer Center, 61-866 Poznan, Poland.
⁴ Medical Physics Department, Greater Poland Cancer Centre, 61-866 Poznan, Poland.
⁵ Medical Faculty, Lodz Medical University, 90-647 Lodz, Poland.

Abstract

According to the international societies' recommendations, the 2-deoxy-2-[¹⁸F]fluoro-D-glucose positron emission tomography/computed tomography ([¹⁸F]FDG PET/CT) technique should not be used as the method of choice in brain tumour diagnosis. Therefore, the brain region can be omitted during standard [¹⁸F]FDG PET/CT scanning. We performed comprehensive literature research and analysed results from 14,222 brain and torso [¹⁸F]FDG PET/CT studies collected in 2010-2020. We found 131 clinically silent primary and metastatic brain tumours and 24 benign lesions. We concluded that the brain and torso [¹⁸F]FDG PET/CT study provides valuable data that may support therapeutic management by detecting clinically silent primary and metastatic brain tumours.

Keywords: 18F-fluorodeoxyglucose; brain tumour; oncology; positron emission tomography.

Publication types

Review